Nerve Sheath Tumors in Neurofibromatosis Type 1: Hannover Med Sch, Dept Nucl Med, Hannover, Germany
Standard
Nerve Sheath Tumors in Neurofibromatosis Type 1: Hannover Med Sch, Dept Nucl Med, Hannover, Germany. / Salamon, Johannes; Papp, László; Tóth, Zoltán; Laqmani, Azien; Apostolova, Ivayla; Adam, Gerhard; Mautner, Victor F; Derlin, Thorsten.
In: PLOS ONE, Vol. 10, No. 12, 01.12.2015, p. e0143305.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Nerve Sheath Tumors in Neurofibromatosis Type 1: Hannover Med Sch, Dept Nucl Med, Hannover, Germany
AU - Salamon, Johannes
AU - Papp, László
AU - Tóth, Zoltán
AU - Laqmani, Azien
AU - Apostolova, Ivayla
AU - Adam, Gerhard
AU - Mautner, Victor F
AU - Derlin, Thorsten
PY - 2015/12/1
Y1 - 2015/12/1
N2 - PURPOSE: To determine the metabolically active whole-body tumor volume (WB-MTV) on F-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) in individuals with neurofibromatosis type 1 (NF1) using a three-dimensional (3D) segmentation and computerized volumetry technique, and to compare PET WB-MTV between patients with benign and malignant peripheral nerve sheath tumors (PNSTs).PATIENTS AND METHODS: Thirty-six NF1 patients (18 patients with malignant PNSTs and 18 age- and sex-matched controls with benign PNSTs) were examined by F-18-FDG PET/CT. WB-MTV, whole-body total lesion glycolysis (WB-TLG) and a set of semi-quantitative imaging-based parameters were analyzed both on a per-patient and a per-lesion basis.RESULTS: On a per-lesion basis, malignant PNSTs demonstrated both a significantly higher MTV and TLG than benign PNSTs (p < 0.0001). On a per-patient basis, WB-MTV and WB-TLG were significantly higher in patients with malignant PNSTs compared to patients with benign PNSTs (p < 0.001). ROC analysis showed that MTV and TLG could be used to differentiate between benign and malignant tumors.CONCLUSIONS: WB-MTV and WB-TLG may identify malignant change and may have the potential to provide a basis for investigating molecular biomarkers that correlate with metabolically active disease manifestations. Further evaluation will determine the potential clinical impact of these PET-based parameters in NF1.
AB - PURPOSE: To determine the metabolically active whole-body tumor volume (WB-MTV) on F-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) in individuals with neurofibromatosis type 1 (NF1) using a three-dimensional (3D) segmentation and computerized volumetry technique, and to compare PET WB-MTV between patients with benign and malignant peripheral nerve sheath tumors (PNSTs).PATIENTS AND METHODS: Thirty-six NF1 patients (18 patients with malignant PNSTs and 18 age- and sex-matched controls with benign PNSTs) were examined by F-18-FDG PET/CT. WB-MTV, whole-body total lesion glycolysis (WB-TLG) and a set of semi-quantitative imaging-based parameters were analyzed both on a per-patient and a per-lesion basis.RESULTS: On a per-lesion basis, malignant PNSTs demonstrated both a significantly higher MTV and TLG than benign PNSTs (p < 0.0001). On a per-patient basis, WB-MTV and WB-TLG were significantly higher in patients with malignant PNSTs compared to patients with benign PNSTs (p < 0.001). ROC analysis showed that MTV and TLG could be used to differentiate between benign and malignant tumors.CONCLUSIONS: WB-MTV and WB-TLG may identify malignant change and may have the potential to provide a basis for investigating molecular biomarkers that correlate with metabolically active disease manifestations. Further evaluation will determine the potential clinical impact of these PET-based parameters in NF1.
U2 - 10.1371/journal.pone.0143305
DO - 10.1371/journal.pone.0143305
M3 - SCORING: Journal article
C2 - 26625155
VL - 10
SP - e0143305
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 12
ER -
